Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
J Phys Chem Lett ; 15(29): 7458-7465, 2024 Jul 25.
Artículo en Inglés | MEDLINE | ID: mdl-39008844

RESUMEN

Controlling reactivity with electric fields is a persistent challenge in chemistry. One approach is to tether ions at well-defined locations near a reactive center. To quantify fields arising from ions, we report crown ethers that capture metal cations as field sources and a covalently bound vibrational Stark shift probe as a field sensor. We use experiments and computations in both the gas and liquid phases to quantify the vibrational frequencies of the probe and estimate the electric fields from the captured ions. Cations, in general, blue shift the probe frequency, with effective fields estimated to vary in the range of ∼0.2-3 V/nm in the liquid phase. Comparison of the gas and liquid phase data provides insight into the effects of mutual polarization of the molecule and solvent and screening of the ion's field. These findings reveal the roles of charge, local screening, and geometry in the design of tailored electric fields.

2.
Cancer Prev Res (Phila) ; : OF1-OF8, 2024 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-38863231

RESUMEN

We aimed to develop a metric for estimating risk for early-onset colorectal cancer (EOCRC) to help decide whether and how to screen persons < age 50. We used risk prediction models derived and validated on male veterans to calculate the RRs for six scenarios: one low-risk scenario (no risk factors present), four intermediate risk scenarios (some risk factors present), and one high-risk scenario (all risk factors present) for three age groups (35-39, 40-44, and 45-49 years). For each scenario, we estimated absolute colorectal cancer risk using Surveillance Epidemiology and End Results colorectal cancer incidence rates and each scenario's RR. We identified the current Surveillance Epidemiology and End Results 5-year age group to which the revised estimate was closest and refer to the midpoint of this group as the "colon age." When the revised estimate equals or exceeds that for 50- to 54-year-olds and for 70- to 74-year-olds, respective recommendations were made for (any) colorectal cancer screening and screening with colonoscopy. Among the scenarios, there was inconsistency between the two models for the 35 to 39 and 40 to 44 age groups, with only the 15-variable model recommending screening for the higher-risk 35- to 39-year-olds. Both models recommended screening for some intermediate risk and high-risk 40- to 44-year-olds. The models were well aligned on whether and how to screen most 45- to 49-year-olds. Using risk factors for EOCRC with colorectal cancer incidence rates, "colon age" may be useful for shared decision-making about whether and how to screen male veterans <50 years. For 45- to 49-year-olds, the 7-variable model may be preferred by patients, providers, and health systems. Prevention Relevance: A new metric known as "colon age" expresses risk of EOCRC based on biological risk and may be useful for providers to explain and for patients to understand colorectal cancer risk when considering whether and how to be screened for colorectal cancer prior to age 45 or 50.

3.
4.
ACS Appl Polym Mater ; 6(9): 4954-4963, 2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38752015

RESUMEN

This study explores the influence of electronic and ionic conductivities on the behavior of conjugated polymer binders through the measurement of entropic potential and heat generation in an operating lithium-ion battery. Specifically, the traditional poly(vinylidene fluoride) (PVDF) binder in LiNi0.8Co0.15Al0.05O2 (NCA) cathode electrodes was replaced with semiconducting polymer binders based on poly(3,4-propylenedioxythiophene). Two conjugated polymers were explored: one is a homopolymer with all aliphatic side chains, and the other is a copolymer with both aliphatic and ethylene oxide side chains. We have shown previously that both polymers have high electronic conductivity in the potential range of NCA redox, but the copolymer has a higher ionic conductivity and a slightly lower electronic conductivity. Entropic potential measurements during battery cycling revealed consistent trends during delithiation for all of the binders, indicating that the binders did not modify the expected NCA solid solution deintercalation process. The entropic signature of polymer doping to form the conductive state could be clearly observed at potentials below NCA oxidation, however. Operando isothermal calorimetric measurements showed that the conductive binders resulted in less Joule heating compared to PVDF and that the net electrical energy was entirely dissipated as heat. In a comparison of the two conjugated polymer binders, the heat dissipation was lower for the homopolymer binder at lower C-rates, suggesting that electronic conductivity rather than ionic conductivity was the most important for reducing Joule heating at lower rates, but that ionic conductivity became more important at higher rates.

5.
Artículo en Inglés | MEDLINE | ID: mdl-38758606

RESUMEN

We aimed to develop a metric for estimating risk for early-onset colorectal cancer (EOCRC) to help decide whether and how to screen persons < age 50. We used risk prediction models derived and validated on male Veterans to calculate the relative risks (RRs) for 6 scenarios: one low-risk scenario (no risk factors present), four intermediate risk scenarios (some factors present), and one high-risk scenario (all factors present) for three age groups (35-39, 40-44, and 45-49 years). For each scenario, we estimated absolute CRC risk using SEER CRC incidence rates and each scenario's RR. We identified the current SEER 5-year age group to which the revised estimate was closest and refer to the midpoint of this group as the "colon age". When the revised estimate was ≥ that for 50-54-year-olds and for 70-74-year-olds, respective recommendations were made for (any) CRC screening and screening with colonoscopy. Among the scenarios, there was inconsistency between the two models for the 35-39 and 40-44 age groups, with only the 15-variable model recommending screening for the higher-risk 35-to-39-year-olds. Both models recommended screening for some intermediate risk and high-risk 40-44-year-olds. The models were well-aligned on whether and how to screen most 45-49-year-olds. Using risk factors for EOCRC with CRC incidence rates, "colon age" may be useful for shared decision making about whether and how to screen male Veterans < 50 years. For 45-49-year-olds, the 7-variable model may be preferred by patients, providers, and health systems.

6.
NEJM Evid ; 3(4): EVIDoa2300236, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38771994

RESUMEN

BACKGROUND: Certain populations have been historically underrepresented in clinical trials. Broadening eligibility criteria is one approach to inclusive clinical research and achieving enrollment goals. How broadened trial eligibility criteria affect the diversity of eligible participants is unknown. METHODS: Using a nationwide electronic health record-derived deidentified database, we identified a retrospective cohort of patients diagnosed with 22 cancer types between April 1, 2013 and December 31, 2022 who received systemic therapy (N=235,234) for cancer. We evaluated strict versus broadened eligibility criteria using performance status and liver, kidney, and hematologic function around first line of therapy. We performed logistic regression to estimate odds ratios for exclusion by strict criteria and their association with measures of patient diversity, including sex, age, race or ethnicity, and area-level socioeconomic status (SES); estimated the impact of broadening criteria on the number and distribution of eligible patients; and performed Cox regression to estimate hazard ratios for real-world overall survival (rwOS) comparing patients meeting strict versus broadened criteria. RESULTS: When applying common strict cutoffs for eligibility criteria to patients with complete data and weighting each cancer type equally, 48% of patients were eligible for clinical trials. Female (odds ratio, 1.30; 95% confidence interval [CI], 1.25 to 1.35), older (age 75+ vs. 18 to 49 years old: odds ratio, 3.04; 95% CI, 2.85 to 3.24), Latinx (odds ratio, 1.46; 95% CI, 1.39 to 1.54), non-Latinx Black (odds ratio, 1.11; 95% CI, 1.06 to 1.16), and lower-SES patients were more likely to be excluded using strict eligibility criteria. Broadening criteria increased the number of eligible patients by 78%, with the strongest impact for older, female, non-Latinx Black, and lower-SES patients. Patients who met only broadened criteria had worse rwOS versus those with strict criteria (hazard ratio, 1.31; 95% CI, 1.27 to 1.34). CONCLUSIONS: Data-driven evaluation of clinical trial eligibility criteria may optimize the eligibility of certain historically underrepresented groups and promote access to more inclusive trials. (Sponsored by Flatiron Health.).


Asunto(s)
Ensayos Clínicos como Asunto , Determinación de la Elegibilidad , Neoplasias , Selección de Paciente , Humanos , Femenino , Neoplasias/terapia , Neoplasias/etnología , Neoplasias/mortalidad , Masculino , Estudios Retrospectivos , Persona de Mediana Edad , Anciano , Adulto , Adolescente , Adulto Joven
7.
Microvasc Res ; 151: 104596, 2024 01.
Artículo en Inglés | MEDLINE | ID: mdl-37625620

RESUMEN

In the later stages of angiogenesis, the vascular sprout transitions into a functional vessel by fusing with a target vessel. Although this process appears to routinely occur in embryonic tissue, the biologic rules for sprout fusion and lumenization in adult regenerating tissue are unknown. To investigate this process, we grafted portions of the regenerating post-pneumonectomy lung onto the chick chorioallantoic membrane (CAM). Grafts from all 4 lobes of the post-pneumonectomy right lung demonstrated peri-graft angiogenesis as reflected by fluorescent plasma markers; however, fluorescent microsphere perfusion primarily occurred in the lobe of the lung that is the dominant site of post-pneumonectomy angiogenesis-namely, the cardiac lobe. Vascularization of the cardiac lobe grafts was confirmed by active tissue growth (p < .05). Functional vascular connections between the cardiac lobe and the CAM vascular network were demonstrated by confocal fluorescence microscopy as well as corrosion casting and scanning electron microscopy (SEM). Bulk transcriptional profiling of the cardiac lobe demonstrated the enhanced expression of many genes relative to alveolar epithelial cell (CD11b-/CD31-) control cells, but only the upregulation of Ereg and Fgf6 compared to the less well-vascularized right upper lobe. The growth of actively regenerating non-neoplastic adult tissue on the CAM demonstrates that functional lumenization can occur between species (mouse and chick) and across the developmental spectrum (adult and embryo).


Asunto(s)
Membrana Corioalantoides , Neovascularización Fisiológica , Ratones , Animales , Membrana Corioalantoides/irrigación sanguínea , Pollos , Neovascularización Patológica , Pulmón
8.
Richard C. Gerkin; Kathrin Ohla; Maria Geraldine Veldhuizen; Paule V. Joseph; Christine E. Kelly; Alyssa J. Bakke; Kimberley E. Steele; Michael C. Farruggia; Robert Pellegrino; Marta Y. Pepino; Cédric Bouysset; Graciela M. Soler; Veronica Pereda-Loth; Michele Dibattista; Keiland W. Cooper; Ilja Croijmans; Antonella Di Pizio; M. Hakan Ozdener; Alexander W. Fjaeldstad; Cailu Lin; Mari A. Sandell; Preet B. Singh; V. Evelyn Brindha; Shannon B. Olsson; Luis R. Saraiva; Gaurav Ahuja; Mohammed K. Alwashahi; Surabhi Bhutani; Anna D'Errico; Marco A. Fornazieri; Jérôme Golebiowski; Liang-Dar Hwang; Lina Öztürk; Eugeni Roura; Sara Spinelli; Katherine L. Whitcroft; Farhoud Faraji; Florian Ph.S Fischmeister; Thomas Heinbockel; Julien W. Hsieh; Caroline Huart; Iordanis Konstantinidis; Anna Menini; Gabriella Morini; Jonas K. Olofsson; Carl M. Philpott; Denis Pierron; Vonnie D. C. Shields; Vera V. Voznessenskaya; Javier Albayay; Aytug Altundag; Moustafa Bensafi; María Adelaida Bock; Orietta Calcinoni; William Fredborg; Christophe Laudamiel; Juyun Lim; Johan N. Lundström; Alberto Macchi; Pablo Meyer; Shima T. Moein; Enrique Santamaría; Debarka Sengupta; Paloma Paloma Domínguez; Hüseyin Yanık; Sanne Boesveldt; Jasper H. B. de Groot; Caterina Dinnella; Jessica Freiherr; Tatiana Laktionova; Sajidxa Mariño; Erminio Monteleone; Alexia Nunez-Parra; Olagunju Abdulrahman; Marina Ritchie; Thierry Thomas-Danguin; Julie Walsh-Messinger; Rashid Al Abri; Rafieh Alizadeh; Emmanuelle Bignon; Elena Cantone; Maria Paola Cecchini; Jingguo Chen; Maria Dolors Guàrdia; Kara C. Hoover; Noam Karni; Marta Navarro; Alissa A. Nolden; Patricia Portillo Mazal; Nicholas R. Rowan; Atiye Sarabi-Jamab; Nicholas S. Archer; Ben Chen; Elizabeth A. Di Valerio; Emma L. Feeney; Johannes Frasnelli; Mackenzie Hannum; Claire Hopkins; Hadar Klein; Coralie Mignot; Carla Mucignat; Yuping Ning; Elif E. Ozturk; Mei Peng; Ozlem Saatci; Elizabeth A. Sell; Carol H. Yan; Raul Alfaro; Cinzia Cecchetto; Gérard Coureaud; Riley D. Herriman; Jeb M. Justice; Pavan Kumar Kaushik; Sachiko Koyama; Jonathan B. Overdevest; Nicola Pirastu; Vicente A. Ramirez; S. Craig Roberts; Barry C. Smith; Hongyuan Cao; Hong Wang; Patrick Balungwe; Marius Baguma; Thomas Hummel; John E. Hayes; Danielle R. Reed; Masha Y. Niv; Steven D. Munger; Valentina Parma.
Preprint en Inglés | medRxiv | ID: ppmedrxiv-20157263

RESUMEN

BackgroundCOVID-19 has heterogeneous manifestations, though one of the most common symptoms is a sudden loss of smell (anosmia or hyposmia). We investigated whether olfactory loss is a reliable predictor of COVID-19. MethodsThis preregistered, cross-sectional study used a crowdsourced questionnaire in 23 languages to assess symptoms in individuals self-reporting recent respiratory illness. We quantified changes in chemosensory abilities during the course of the respiratory illness using 0-100 visual analog scales (VAS) for participants reporting a positive (C19+; n=4148) or negative (C19-; n=546) COVID-19 laboratory test outcome. Logistic regression models identified singular and cumulative predictors of COVID-19 status and post-COVID-19 olfactory recovery. ResultsBoth C19+ and C19-groups exhibited smell loss, but it was significantly larger in C19+ participants (mean{+/-}SD, C19+: -82.5{+/-}27.2 points; C19-: -59.8{+/-}37.7). Smell loss during illness was the best predictor of COVID-19 in both single and cumulative feature models (ROC AUC=0.72), with additional features providing negligible model improvement. VAS ratings of smell loss were more predictive than binary chemosensory yes/no-questions or other cardinal symptoms, such as fever or cough. Olfactory recovery within 40 days was reported for [~]50% of participants and was best predicted by time since illness onset. ConclusionsAs smell loss is the best predictor of COVID-19, we developed the ODoR-19 tool, a 0-10 scale to screen for recent olfactory loss. Numeric ratings [≤]2 indicate high odds of symptomatic COVID-19 (4

9.
Valentina Parma; Kathrin Ohla; Maria G. Veldhuizen; Masha Y. Niv; Christine E. Kelly; Alyssa J. Bakke; Keiland W. Cooper; Cédric Bouysset; Nicola Pirastu; Michele Dibattista; Rishemjit Kaur; Marco Tullio Liuzza; Marta Y. Pepino; Veronika Schöpf; Veronica Pereda-Loth; Shannon B Olsson; Richard C Gerkin; Paloma Rohlfs Domínguez; Javier Albayay; Michael C. Farruggia; Surabhi Bhutani; Alexander W Fjaeldstad; Ritesh Kumar; Anna Menini; Moustafa Bensafi; Mari Sandell; Iordanis Konstantinidis; Antonella Di Pizio; Federica Genovese; Lina Öztürk; Thierry Thomas-Danguin; Johannes Frasnelli; Sanne Boesveldt; Özlem Saatci; Luis R. Saraiva; Cailu Lin; Jérôme Golebiowski; Liang-Dar Hwang; Mehmet Hakan Ozdener; Maria Dolors Guàrdia; Christophe Laudamiel; Marina Ritchie; Jan Havlícek; Denis Pierron; Eugeni Roura; Marta Navarro; Alissa A. Nolden; Juyun Lim; KL Whitcroft; Lauren R. Colquitt; Camille Ferdenzi; Evelyn V. Brindha; Aytug Altundag; Alberto Macchi; Alexia Nunez-Parra; Zara M. Patel; Sébastien Fiorucci; Carl M. Philpott; Barry C. Smith; Johan N Lundström; Carla Mucignat; Jane K. Parker; Mirjam van den Brink; Michael Schmuker; Florian Ph.S Fischmeister; Thomas Heinbockel; Vonnie D.C. Shields; Farhoud Faraji; Enrique Enrique Santamaría; William E.A. Fredborg; Gabriella Morini; Jonas K. Olofsson; Maryam Jalessi; Noam Karni; Anna D'Errico; Rafieh Alizadeh; Robert Pellegrino; Pablo Meyer; Caroline Huart; Ben Chen; Graciela M. Soler; Mohammed K. Alwashahi; Olagunju Abdulrahman; Antje Welge-Lüssen; Pamela Dalton; Jessica Freiherr; Carol H. Yan; Jasper H. B. de Groot; Vera V. Voznessenskaya; Hadar Klein; Jingguo Chen; Masako Okamoto; Elizabeth A. Sell; Preet Bano Singh; Julie Walsh-Messinger; Nicholas S. Archer; Sachiko Koyama; Vincent Deary; S. Craig Roberts; Hüseyin Yanik; Samet Albayrak; Lenka Martinec Novákov; Ilja Croijmans; Patricia Portillo Mazal; Shima T. Moein; Eitan Margulis; Coralie Mignot; Sajidxa Mariño; Dejan Georgiev; Pavan K. Kaushik; Bettina Malnic; Hong Wang; Shima Seyed-Allaei; Nur Yoluk; Sara Razzaghi; Jeb M. Justice; Diego Restrepo; Julien W Hsieh; Danielle R. Reed; Thomas Hummel; Steven D Munger; John E Hayes.
Preprint en Inglés | medRxiv | ID: ppmedrxiv-20090902

RESUMEN

Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and chemosensory impairments such as anosmia. However, these reports have downplayed or failed to distinguish potential effects on taste, ignored chemesthesis, generally lacked quantitative measurements, were mostly restricted to data from single countries. Here, we report the development, implementation and initial results of a multi-lingual, international questionnaire to assess self-reported quantity and quality of perception in three distinct chemosensory modalities (smell, taste, and chemesthesis) before and during COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 8 other, ages 19-79) reported a COVID-19 diagnosis either via laboratory tests or clinical assessment. Importantly, smell, taste and chemesthetic function were each significantly reduced compared to their status before the disease. Difference scores (maximum possible change {+/-}100) revealed a mean reduction of smell (-79.7 {+/-} 28.7, mean {+/-} SD), taste (-69.0 {+/-} 32.6), and chemesthetic (-37.3 {+/-} 36.2) function during COVID-19. Qualitative changes in olfactory ability (parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, perceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments were similar between participants in the laboratory test and clinical assessment groups. These results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis. The multimodal impact of COVID-19 and lack of perceived nasal obstruction suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.

10.
Rev. cuba. med ; 50(4): 465-469, oct.-dic. 2011.
Artículo en Español | LILACS | ID: lil-615459

RESUMEN

La biopsia renal percutánea (BRP) es indicada en la actualidad en gran número de situaciones clínicas, pues constituye un proceder razonablemente seguro y de apreciables dividendos en la atención de los pacientes afectos de enfermedades renales o de enfermedades sistémicas que involucran el riñón. Es utilizada para establecer diagnósticos exactos, escoger la terapéutica idónea y precisar el grado de actividad (reversibilidad potencial) o cronicidad (irreversibilidad) de las lesiones por lo que, además, tiene gran importancia en el establecimiento del pronóstico y las probabilidades de respuesta al tratamiento de múltiples afecciones. La evaluación rutinaria de la biopsia renal implica el examen del espécimen por microscopia de luz, de inmunofluorescencia y electrónica. Se ha convertido en un pilar diagnóstico insustituible en la práctica nefrológica. Sin embargo, para que esto llegara a ser una realidad, se han tenido que dar múltiples pasos a lo largo de la historia y, como luego veremos, los investigadores de Cuba han desempeñado una función trascendente en este desarrollo...


Asunto(s)
Biopsia con Aguja Fina/métodos , Enfermedades Renales/diagnóstico , Cuba
11.
Rev. cuba. med ; 50(4)oct.-dic. 2011.
Artículo en Español | CUMED | ID: cum-57079

RESUMEN

La biopsia renal percutánea (BRP) es indicada en la actualidad en gran número de situaciones clínicas, pues constituye un proceder razonablemente seguro y de apreciables dividendos en la atención de los pacientes afectos de enfermedades renales o de enfermedades sistémicas que involucran el riñón. Es utilizada para establecer diagnósticos exactos, escoger la terapéutica idónea y precisar el grado de actividad (reversibilidad potencial) o cronicidad (irreversibilidad) de las lesiones por lo que, además, tiene gran importancia en el establecimiento del pronóstico y las probabilidades de respuesta al tratamiento de múltiples afecciones. La evaluación rutinaria de la biopsia renal implica el examen del espécimen por microscopia de luz, de inmunofluorescencia y electrónica. Se ha convertido en un pilar diagnóstico insustituible en la práctica nefrológica. Sin embargo, para que esto llegara a ser una realidad, se han tenido que dar múltiples pasos a lo largo de la historia y, como luego veremos, los investigadores de Cuba han desempeñado una función trascendente en este desarrollo...


Asunto(s)
Biopsia con Aguja Fina/métodos , Enfermedades Renales/diagnóstico , Cuba
13.
St. Louis, Missouri; Mosby; 1997. 304 p. ilus.
Monografía en Inglés | Sec. Munic. Saúde SP, HSPM-Acervo | ID: sms-4292

RESUMEN

Our primary reason for writing this book is to help physicians interested in ultrasonography get started. While the scope and importance of ultrasonography has grown tremendously over the past several decades, the strategy for introducing ultrasonography into nontraditional settings of emergency medicine and primary care deserves special attention. The photographs, artist’s drawings, and graphics are selected to illustrate basic concepts as well as to provide a framework for more advanced use of the technology. Our aim is to make ultrasonography as accessible and clinically relevant as possible. The term “goal-directed ultrasound” means using the images as an integral part of the diagnostic and therapeutic process. Finally, this book is designed to get nonradiologists excited about the possibilities ultrasound can offer. We started out looking for the obvious right upper quadrant and pelvic pathologic conditions. Then we added the aorta and blood in the abdomen as a result of trauma and then blood around the heart. Later we began to visualize the internal jugular vein before placing our central venous lines and we looked at the heart during medical codes to definitively document pulseless electrical activity (PEA). More recently, we began looking at the kidneys to identify hydronephrosis, leg veins to assess for deep venous thrombosis, the space above the diaphragm to look for pleural effusion, and the soft tissues to identify foreign bodies or abscess formation. All these subjects and more are discussed in this book. Just before this text went to print we discovered another use for ultrasonography that has never been discussed in the literature. We had a morbidly obese patient from whom we were unable to obtain spinal fluid even with by visualizing the echos caused by her spine. The applications are exciting and can have a significant impact on the quality of patient care


Asunto(s)
Ultrasonografía , Diagnóstico , Servicios Médicos de Urgencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA